• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology

Article

People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.

People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.

“Right now we are looking at progression-free, stable disease as almost a win,” she said.

Keeping that in mind, Michael Kolodziej, MD, expects the rules will change, although he is skeptical that non-traditional endpoints will start to be implemented. The way those would be used, he said, would be to distinguish one of the many PD-1, PD-L1 drugs from the others.

“I think patient-reported outcomes are sorely lacking from the vast majority of work that has been done in oncology,” Dr Kolodziej said. “If we could find a way to collect that data and tie it to other more traditional endpoints that would be a great service.”

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.